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Abstract
Background: Steroid receptors play major roles in the development, differentiation, and homeostasis of normal
and malignant tissue. STAMP is a novel coregulator that not only enhances the ability of p160 coactivator family
members TIF2 and SRC-1 to increase gene induction by many of the classical steroid receptors but also modulates
the potency (or EC50) of agonists and the partial agonist activity of antisteroids. These modulatory activities of
STAMP are not limited to gene induction but are also observed for receptor-mediated gene repression. However, a
physiological role for STAMP remains unclear.
Methods: The growth rate of HEK293 cells stably transfected with STAMP plasmid and overexpressing STAMP
protein is found to be decreased. We therefore asked whether different STAMP levels might also contribute to the
abnormal growth rates of cancer cells. Panels of different stage human cancers were screened for altered levels of
STAMP mRNA. Those cancers with the greatest apparent changes in STAMP mRNA were pursued in cultured
cancer cell lines.
Results: Higher levels of STAMP are shown to have the physiologically relevant function of reducing the growth of
HEK293 cells but, unexpectedly, in a steroid-independent manner. STAMP expression was examined in eight
human cancer panels. More extensive studies of ovarian cancers suggested the presence of higher levels of STAMP
mRNA. Lowering STAMP mRNA levels with siRNAs alters the proliferation of several ovarian cancer tissue culture
lines in a cell line-specific manner. This cell line-specific effect of STAMP is not unique and is also seen for the
conventional effects of STAMP on glucocorticoid receptor-regulated gene transactivation.
Conclusions: This study indicates that a physiological function of STAMP in several settings is to modify cell
growth rates in a manner that can be independent of steroid hormones. Studies with eleven tissue culture cell
lines of ovarian cancer revealed a cell line-dependent effect of reduced STAMP mRNA on cell growth rates. This
cell-line dependency is also seen for STAMP effects on glucocorticoid receptor-mediated transactivation. These
preliminary findings suggest that further studies of STAMP in ovarian cancer may yield insight into ovarian cancer
proliferation and may be useful in the development of biomarker panels.
Background
Cell proliferation is a complicated and poorly under-
stood process with contributions from many factors.
Consequently identifying the causes for abnormal cell
propagation, such as in cancers, has been an even more
daunting task. Recent evidence suggests that mutant
pathways (produced by a variety of mutant or dysregu-
lated proteins) as opposed to a single mutant or dysre-
gulated protein are responsible for at least some cancers
[1]. One pathway that is well known for its role with
normal cell growth and differentiation involves the clas-
sical steroid receptors. Androgen (ARs), estrogen (ERs),
and progesterone receptors (PRs) are best recognized
for their contribution in the morphogenesis of reproduc-
tive tissues [2-4]. Conversely, preventing the actions of
ARs and ERs has been the major treatment of choice
for many years in combating hormone-sensitive prostate
and breast cancers respectively [5,6]. Glucocorticoids are
clinically invaluable in treating lymphoid cancers and
attenuating immune responses [7] while mineralocorti-
coid agonists are now thought to have significant effects
on the heart and vasculature [8,9]. A major component
in the expression of steroid receptor-regulated gene
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cally elevate or inhibit the action of receptor-agonist
complexes [10-14].
STAMP is a novel coregulator that enhances the abil-
ity of p160 coactivator family members TIF2 and SRC-1
to augment gene induction by AR, glucocorticoid recep-
tor (GR), and PR. STAMP also modulates the potency
(or EC50) of agonists and the partial agonist activity of
antisteroids [15,16]. These modulatory activities of
STAMP are not limited to gene induction but are also
observed for GR-mediated gene repression [17]. These
actions appear to proceed via the binding of internal
and C-terminal regions of STAMP to coactivators and
receptors respectively in a manner that includes steroid-
mediated recruitment of STAMP to the enhancer region
of regulated genes. Interestingly, STAMP does not inter-
act with ER or members of the nuclear receptor sub-
family such as thyroid receptor, PPAR, RAR, or RXR
[15].
The physiological role of STAMP, however, remains
unclear. The absence of STAMP paralogs in the human
genome suggests an important function. STAMP has
been included as a member of the tyrosine tubulin
ligase-like (TTLL) family [18] on the basis of containing
a tyrosine tubulin ligase (TTL) domain. However, this
grouping is not applicable to several of the biological
function assays of STAMP in that the coregulatory
activity of STAMP with GRs does not require the TTL
domain [15]. Differential detection in Northern blots
[15] and qPCR analysis of mouse tissues (G-S Lee and
SS Simons, unpublished) is consistent with a role for
STAMP in brain, ovaries, and testes. In addition, the
importance of steroid receptors in normal and aberrant
cell growth combined with STAMP binding to, and
modulating the activity of, AR, GR, and PR suggests a
possible role for STAMP in regulating the growth of
some cells and cancers.
Ovarian cancer is the fifth most common cancer in
the United States and is responsible for 4% of new can-
cer cases, and 5% of the cancer deaths, occurring in
women each year [19,20]. The major cause of death is
from epithelial ovarian tumors, which constitute the
large majority of ovarian cancers [21]. Ovarian cancer in
general has a 5-year survival rate of over 90% if diag-
nosed and treated early, when the cancer is confined to
the ovaries. Unfortunately, due to ovarian cancer’sn o n -
specific symptoms and the lack of reliable early detec-
tion methods, only about 20% of all cases are found at
this beginning stage. If caught in an advanced stage, the
5-year survival rate can be as low as 29% [22,23]. The
inability to identify and treat this cancer early under-
scores the necessity for better understanding its biology
and unique gene and protein expression panels. Unfor-
tunately, the heterogeneity of epithelial ovarian cancers
complicates this task. It has recently been suggested that
ovarian cancer, like breast cancer, may be subdivided by
differences in gene expression panels [24,25]. Therefore,
it is likely that the mechanism(s) of ovarian cancer
growth and metastasis will involve multiple biochemical
pathways, as has been concluded for pancreatic and
breast cancers [1,26].
We now report that STAMP has the physiologically
relevant effect of influencing the growth rate of some
cells in a manner that appears independent of steroid
hormones. Of potential clinical interest is our finding
that STAMP mRNA levels are elevated in human ovar-
ian cancer samples (stages I-IV), although the effects of
STAMP levels on ovarian cancer cell growth vary. We
suggest that the effects of STAMP are cell-line depen-
dent and further investigation into this unique finding
may advance our understanding of tumorigenesis and
progression of some human ovarian cancers.
Methods
Cell lines and reagents
Various epithelial ovarian cancer cell lines were obtained
as gifts: SHIN3 and OVCAR5 from Mark Levine
(NIDDK), and A1847, A2780, IGROV1, OVCAR10,
PEO-1, and 2008 from Charles Drescher and Beatrice
Knudsen (Fred Hutchinson Cancer Research Center,
Seattle WA). Renilla TS wasag i f tf r o mN a s r e l d i nM .
Ibrahim, Otto Fröhlich, and S. Russ Price (Emory
University School of Medicine). STAMP SMART-
pool siRNA was purchased from Dharmacon (#M-
015406), Lamin A/C siRNA from Qiagen (#1027320),
STAMP Taqman gene expression assay probe
(#Hs00367300_m1) and human GAPDH control probe
(#4310884E) from ABI, and siLentFect siRNA transfec-
tion reagent from Bio-Rad #170-3361. GR plasmid
(pSVLGR) is a gift from Keith Yamamoto (Univ. of Cal.,
SF). The CellTiter 96 AQueous One Solution cell
growth assay is supplied by Promega. Mouse monoclo-
nal anti-TIF2 antibody is from Bethyl Labs (#A300-
345A). Rabbit polyclonal anti-a-tubulin antibody (used
at 15 ng/ml) is from Abcam (#ab4074). The following
primers were used for qRT-PCR of both human and rat
GR (numbers in parentheses are positions in human GR
cDNA): GTCTTCAGGCTGGAATGAACC (1443-1462)
and CTTTGCCCATTTCACTGCTGC (1737-1717).
Stably transfected 293 cells
HEK293 cells were always grown in high glucose
DMEM (Invitrogen) with 10% fetal bovine serum,
sodium pyruvate (Cellgro), and MEM nonessential
amino acids (Cellgro) to 70% confluency in 100 mm
dishes. Cells were transfected with 10 μgo fF L A G -
STAMP/pCDNA3.1neo or pCDNA3.1neo using 23 μl
Fugene 6 (Roche Diagnostics, Branford, CT) for 24 hr.
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24 hr before being washed (PBS without Ca
++/Mg
++;
Invitrogen), trypsinized, diluted 1:50-1000 in media con-
taining 1 mg/ml G418 (Invitrogen), plated in 100 mm
dishes and grown for 14 days. Colonies were selected
and expanded first in 24 well plates for 10 days and
then in 6 well plates until there were enough cells, all
with 0.5 mg/ml G418. Positive clones were tested for
Flag-STAMP expression by Western blotting with anti-
STAMP antibody prepared by Covance (3
rd bleed,
HL5761). All HEK293 stable cells used for experiments
were grown in media free of G418 for at least 2 weeks
unless otherwise noted.
Cell growth assay
Cells were washed (PBS without Ca
++/Mg
++),t r y p s i -
nized, and then seeded at 10,000 cells/well in 96 well
culture plates. Cell growth at the indicated points (day
of seeding = Day 0) was determined by adding 20 μlo f
CellTiter One Solution/well and measuring the OD492
3 hours later in a Beckman Count DTX880 as recom-
mended by the supplier (Promega). Medium without
cells was used as the blank control.
FACS and cell counting
Cells (grown with 0.1 mg/ml G418) were washed 3
times with PBS without calcium or magnesium (Invitro-
gen), counted with a Beckman Coulter Vi-Cell XR2.02,
and seeded at 50,000 viable cells/well in 6 well dishes in
3 ml of medium without G418. After 24 hours, the cells
were washed once with PBS, trypsinized, resuspended in
500 μl of medium, and placed on ice. Cells were incu-
bated at 0°C with 1 μl of 5 mg/ml of propidium iodide
(Invitrogen) immediately prior to analysis on a Becton
Dickinson FacsCalibur flow cytometry system and
counting with a Beckman Coulter Vi-Cell XR2.02.
Tissue scan panels for endogenous STAMP determination
Tissue Scan panels (8 common cancers [#CSRT101],
kidney cancer [#HKRT101], ovarian cancer [#HORT101
and HORT102], and breast cancer [#BCRT101]) and the
accompanying pathology and tumor staging reports are
available from OriGene (Rockville, MD). Each panel
contains pre-normalized cDNA arrays prepared from
pathologist-verified tumor tissues. Each well of the panel
has same amount total cDNA. Thus, any target gene (e.
g. STAMP) variation in different wells reflects real
changes between tumor samples. Quantitative real-time
PCR (qRT-PCR) was run once for each panel (plate)
using validated STAMP primers according to manufac-
turer’s instructions. To determine the absolute level of
STAMP, 10 μl 2× Taqman PCR master, 1 μlS T A M P
Taqman probe, and 9 μl water (total 20 μl) was added
to each well of the 96 well plate, as recommended by
OriGene. Then real-time qRT-PCR was run on an ABI
HT 7900 according to the manufacturer’s instructions.
Transient transfections of stably transfected cells
withsiRNAs or plasmids
For 6 well plates, cells were seeded at 5000 per well one
day before transfection. One hour before transfection,
1.25 ml of fresh medium was added. siRNA (75 pM)
was incubated for 20 min at r.t. with 1 μl siLentFect
reagent in Opti-mem medium (total of 250 μl) before
being added to Opti-mem medium in each well (final
concentration of siRNA = 50 nM). For 96 well plates,
cells were seeded at 500-2000 per well and 50 μlo f
fresh medium was added one hour before transfection.
Then 3.5 pM of siRNA was mixed with 0.05 μl siLent-
Fect in a total of 20 μlo fO p t i - m e mm e d i u mf o r2 0
min before being added to each well. One day later,
fresh medium was added to each well in both protocols.
Total RNA isolation, reverse transcription, real-time
PCR, and luciferase assays of transiently transfected
GREtkLUC were performed as previously described [15].
For transient transfection experiments with GREtkLUC,
VA (1 × 10
4)o rS 1 3( 2×1 0
4) cells in 300 μlo fm e d i a
were transfected for 24 hr using 0.8 μl/well of Fugene 6
and either 0, 10 or 30 ng pSVLGR plus 100 ng GREtk-
Luc and 10 ng Renilla TS. Total transfected DNA was
maintained at 300 ng/well with PBSK+. The cells were
then induced with steroids in fresh media for 24 hr,
separated from the media, and lysed for 20 min with
300 μl of passive lysis buffer (Promega) at room tem-
perature on a rotating shaker. Lysate (50 μl) was then
loaded into 96 well luminometer plates and read in a
Berthold luminometer.
Statistical analysis
Unless otherwise noted, the values of n independent
experiments, performed in triplicate for Luciferase assays,
were analyzed for statistical significance by the two-tailed
Student’s t test using InStat 2.03 (GraphPad Software, San
Diego, CA). In every case, each average of triplicates was
treated as one value of the n experiments. When the dif-
ference between the SDs of two populations was signifi-
cantly different, the Mann-Whitney or Alternate Welch t
test was used. A nonparametric test was used if the distri-
bution of values was non-Gaussian. Best-fit curves (R
2
almost always ≥ 0.95) following Michaelis-Menten kinetics
were obtained for the dose-response experiments with
KaleidaGraph (Synergy Software, Reading, PA).
Results
STAMP overexpression decreases growth of human
embryonic kidney 293 cells
Two colonies of 293 cells containing stably transfected
STAMP were selected for study. Both colonies gave less
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transfected empty vector (clone VA) after 3-4 days, as
determined by counting of isolated cells (43 ± 19% [S.
D., n = 9] and 33 ± 7% [S.D., n = 2] for clones 13 and
10 respectively vs. VA cells). One colony (clone S13)
was selected for further study. When removed from
G418 selection and immediately examined by “Cell
Titre” assay, clone S13 cells show a 65% reduction in
cell replication (Fig. 1A). Automated cell counting gave
similar results (data not shown). FACS analysis showed
no increase in the proportion of dead cells in S13 vs.
VA cells (Figs. 1B&C). Thus, the lower density of S13
cells over time is due to slower growth as opposed to
increased cell death.
Given the undetectable level of STAMP in VA cells by
Western blotting (data not shown), qRT-PCR was used
to determine the relative amounts of STAMP. STAMP
mRNA in clone S13 was 32-fold higher than in VA cells
but decreased by a factor of two to 14-fold after with-
drawal from G418 for a least 3 months. As expected,
these reduced levels of excess STAMP were reflected in
a smaller reduction of cell growth, with or without glu-
cocorticoid (Fig. 1D). The growth rate of clone S13 as a
percent of clone VA cells was the same with EtOH (77
± 0.02%; S.E.M, n = 10, P < 0.0001) and Dex (76 ±
0.03%; S.E.M., n = 9, P < 0.0002).
In view of the ability of STAMP to also alter the
induction properties of PR and AR [15,16], we asked if
the addition of any other steroids could influence the
growth of clone S13 vs. control (clone VA) cells. As
shown in Fig. 1E, saturating levels for receptor binding
of progestin (R5020), androgen (R1881), or mineralocor-
ticoid (aldosterone) also did not change the growth rate
of cells with or without overexpressed STAMP.
STAMP levels in human tumor samples
In view of the effect of STAMP on 293 cell growth, we
asked if the abnormal growth of any cancers might be
influenced by the levels of endogenous STAMP. Stan-
dardized amounts of cDNAs from each stage of 8 com-
mon human cancers were obtained from OriGene.
Quantitative real time PCR analysis with STAMP Taq-
Man probes was performed to determine the amount of
STAMP mRNA in each tumor sample (Additional file 1:
Table S1). As shown in Fig. 2A where the results from
individual samples are plotted, this preliminary screen
suggested that STAMP levels in kidney cancers gradu-
ally decrease as the tumor stage progresses while
STAMP levels might be elevated in Stage I of ovarian
cancers and several stages of breast cancer.
These pilot-study observations were pursued by analyz-
ing larger panels containing 48 samples from various
stages of these three cancers. This more extensive study
displayed no significant differences in STAMP levels
among various kidney and breast cancer samples (data
not shown). However, data from a total of 83 additional
samples in two other ovarian cancer panels revealed a
statistically significant, two-fold elevation of STAMP
mRNA in tumors of stages I-III relative to “normal”
ovarian tissue (n = 13) (Fig. 2B; see Additional file 2:
Table S2 for description and grading of samples plus
the raw qPCR data). We recognize that this result may
be misleading as the “normal” is most likely enriched
for normal ovarian stroma, which is nearly devoid of
epithelial cells that are found primarily on the capsular
surface of the ovary. The difference between overt Stage
I-III cancers and the three low malignant potential, bor-
derline tumors (IGB) is significant (P = 0.033 by one-
tailed Student t-test) because low malignant potential
ovarian neoplasm is a nonmalignant but epithelial pro-
cess. These two findings led us to further investigate the
role of STAMP in ovarian cancer.
Nine cultured ovarian cancer cell lines were examined:
Hey A8, SKOV3, OVCAR8, A1847, PEO-1, OVCAR10,
A2780, 2008, and IGROV1. The STAMP levels in three
randomly selected, untreated cell lines (Hey A8, SKOV3,
OVCAR8) were determined and normalized to the
amount in Hey A8 cells, which was arbitrarily selected
as a reference value. STAMP mRNA levels in these
ovarian cancer cell lines do not appear abnormal. They
are slightly higher than that in two other transformed
cell lines (U2OS.rGR osteosarcoma cells with stably
transfected GR and the control 293 VA cells) and much
less than in the clone S13 293 cells with stably trans-
fected STAMP (Table 1).
Role of STAMP in proliferation of ovarian cancer cells
Because elevated STAMP decreases the growth rate of
293 cells (Fig. 1), we asked if lowering the levels of endo-
genous STAMP with transfected STAMP siRNA would
increase the growth rate of the ovarian cancer cells. After
transfecting the cells with either Lamin siRNA, as a con-
trol, or a SMARTpool (Dharmacon) of STAMP siRNAs,
we again determined the STAMP levels. On average,
STAMP siRNA reduced the level of endogenous STAMP
mRNA in each cell line to 28 ± 8% (S.D., n = 7 cell lines,
each being the average of three independent experi-
ments) of that seen in the same cells treated with the
Lamin siRNA control (Table 2; “percent remaining”).
The “absolute” values of STAMP mRNA in each cell line
following STAMP siRNA treatment, after adjusting for
the different initial levels in each cell line, are also given
Table 2 (values are expressed relative to Hey A8 refer-
ence cells, with STAMP levels in Hey A8 cells treated
with Lamin siRNA = 100). Unexpectedly, a reduced
amount of STAMP mRNA now inhibits the growth of
Hey A8, A1847 and IGROV1 cells, in each case com-
pared to the growth of the same cells treated with Lamin
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Page 4 of 11Figure 1 Effect of stably transfected STAMP on the growth rate of 293 cells. (A) Increased STAMP decreases cell growth. The number of
cells in replicate plates of clone S13 (S) and VA (V) cells (no steroid, cells removed from G418 1 day prior) after increasing days was assessed by
the CellTiter One Solution assay. The average value (± S.E.M.) of four independent experiments is shown. **P < 0.005, ***P < 0.0005. (B&C) FACS
analysis of VA and S13 cells (no steroid, cells removed from G418 upon seeding; S = single cells, D = double cells). The number of dead cells
after increasing days in one of three representative experiments is plotted in C (± SD, n = 3, *P < 0.05, **P < 0.005). (D) Growth of VA and S13
cells after removal from G418 for more than 1 month. Experiment was conducted and plotted (± S.E.M., n = 4, *P < 0.05) as in A except that 1
μM Dex was added to cells as indicated. (E) Increased STAMP decreases cell growth ± steroid. Experiment was conducted as in D except that
four different steroids (100 nM aldosterone, 1 μM Dex, 20 nM R5020, and 10 nM R1881) were added. Similar results were obtained in two
additional independent experiments. In some cases (e.g., S13 cells in Fig. 1A), the error bar length is smaller than the symbol.
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have the opposite (and initially predicted) effect on the
proliferation of PEO-1 and 2008 cells, which are signifi-
cantly increased. Finally, reduced STAMP mRNA levels
cause no change in the propagation of SKOV3,
OVCAR8, OVCAR10, A2780 and two other ovarian can-
cer cell lines (SHIN3 and OVCAR5) (Fig. 3A).
In view of the different growth responses to lowered
STAMP levels in the ovarian cancer cell lines, it seemed
possible that the absolute level of STAMP, as opposed
to the relative amount, might be a critical determinant
for growth rates. In this case, cells with high levels of
STAMP mRNA after siRNA treatment, relative to
HeyA8 (see “absolute” values in Table 2), might have
different growth rates than those with much lower
levels. However, PEO-1 and IGROV1 cells have similar
levels of STAMP mRNA after STAMP siRNA treatment
("absolute” in Table 2) but very different growth rates
(Fig. 3A). The growth response of the cells treated with
STAMP siRNA (Table 2) are plotted in Fig. 3B. This
clearly shows that there is no correlation between the
amount of STAMP mRNA in STAMP siRNA-treated
cells and the growth rate of STAMP siRNA-treated cells
as a percent of Lamin siRNA-treated cells. These data
suggest that neither absolute nor relative levels of
STAMP uniquely control the growth rates of these ovar-
ian cancer cells. In this case, the effects of decreased
intracellular STAMP on cell growth would depend on
additional factors in a cell-dependent manner.
The levels of proteins and kinases known to be asso-
ciated with cancer proliferation and/or apoptosis (p21,
p53, ERK, phospho-ERK, AKT, phospho-AKT and
cleaved PARP) were examined in the background of
STAMP or Lamin silencing to determine if they paral-
leled the growth rates of the ovarian cancer cells with
reduced amounts of STAMP mRNA. No relationship
was observed between the expression level of these pro-
teins/kinases on Western blots and the growth rates of
A1847, A2780, HeyA8, IGROV1, OVCAR10, PEO-1,
and 2008 cells (data not shown). We conclude that
changing the intracellular concentration or activation
status of any of these proteins does not mediate the
effects of STAMP levels on the growth rates of the ovar-
ian tissue culture cells.
Overexpressed STAMP in stably transfected 293 cells
alters properties of GR-mediated transactivation in a
cell-specific manner
We speculated that the ability of higher levels of
STAMP to produce opposite effects on the growth
of 293 and ovarian cancer cells could be due to cell-
Figure 2 Levels of STAMP mRNA in different human tumor samples. (A) Survey of eight human tumor types. Levels of STAMP mRNA in
individual samples of OriGene Tissue Scan panel (each bar corresponds to a single tissue sample) were determined as described in Materials
and Methods and plotted (relative to the STAMP mRNA level of the first sample in the Breast panel) vs. tumor stage. (B) STAMP mRNA in human
ovarian cancers. Levels of STAMP mRNA in two different large scale OriGene Tissue Scan panels of only ovarian cancers was determined as in A.
The data from both panels were combined and plotted (box plot) as percent of the average STAMP level in normal (Stage 0) samples (n = 13)
for the different stages (n for Stage IGB [low malignant potential] = 3, Stage I = 12, Stage II = 12, Stage III = 34, Stage IV = 9). P values were
determined for ΔCt values from the qRT-PCR assay before conversion to percent of STAMP in normal samples, which was plotted.
Table 1 Relative STAMP mRNA levels in ovarian cancer
tissue culture cells
Cells: Hey A8 SKOV 3 OVCAR 8 U2OS.rGR 293 clone
VA
293 clone
S13
Level: 100 269 ± 67 113 ± 8 59 ± 6 149 1864
STAMP mRNA levels in the indicated cells were determined by qRT-PCR as
described in Materials and Methods and then normalized to that seen in
HeyA8 cells (which was arbitrarily selected as reference). Values are the
averages ± S.E.M. of 3 experiments (one experiment for 293 cells).
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same cell-specific differences might also reverse the
effects of STAMP on the parameters of GR-regulated
gene expression. Previous studies revealed that transi-
ently transfected STAMP in both CV-1 and U2OS.rGR
cells not only augment the maximal amount of Dex
activity (Amax), and the partial agonist activity of anti-
steroids (expressed as percent of maximum Dex activ-
ity), but also shift the dose-response curve (and EC50)
for gene induction to lower concentrations of steroid
[15-17]. We therefore asked whether the elevated
STAMP levels in 293-derived clone S13 cells would
reduce the EC50 of the dose-response curve for GR
induction of exogenous GREtkLUC reporter relative to
the same treatment of vector control VA cells. We used
the identical exogenous reporter gene (GREtkLUC) as in
our previously published studies [15-17] in order to
minimize the differences inherent upon comparing gene
induction properties in different cell lines. Due to the
relatively low level of GR in 293 cells, we concentrated
o nt h ee f f e c t so fS T A M Pi nt h ep r e s e n c eo ft w o
amounts (10 and 30 ng) of transiently transfected GR
plasmid. As expected, the magnitude of change in each
parameter was proportional to the amount of trans-
fected GR plasmid [14]. With both amounts of trans-
fected GR, however, the higher level of STAMP in clone
Table 2 Relative STAMP mRNA levels in ovarian cancer tissue culture cells after siRNA treatment
Cells: Hey A8 A1847 PEO-1 OVCAR10 A2780 2008 IGROV1
Percent remaining: 29 ± 5 13 ± 3 33 ± 6 25 ± 5 33 ± 9 23 ± 3 38 ± 4
Absolute STAMP mRNA relative to HeyA8): 29 ± 5 16 ± 2 47 ± 12 208 ± 37 110 ± 32 30 ± 6 43 ± 14
STAMP mRNA levels in the indicated cells with transfected siRNA were determined by qRT-PCR as described in Materials and Methods and then normalized to
that seen in HeyA8 cells (which was arbitrarily selected as reference) after transient transfection with Lamin siRNA. The data show both the percent remaining
STAMP mRNA after siRNA treatment (i.e., 100 × STAMP siRNA/Lamin siRNA) and the “absolute” levels relative to STAMP in HeyA8 cells treated with Lamin siRNA.
For this normalization to STAMP in Lamin siRNA-treated HeyA8 cells, the ratio (×100) of (STAMP mRNA in each STAMP siRNA-treated cell)/(STAMP mRNA in
STAMP siRNA-treated HeyA8 cells) is multiplied by the ratio of (STAMP mRNA in STAMP siRNA-treated HeyA8 cells)/(STAMP in Lamin siRNA treated HeyA8 cells) in
the same experiment (values ranged from 0.22 to 0.38). Values are the averages ± S.E.M. of 3 experiments.
Figure 3 Effect of STAMP siRNA on growth of ovarian cancer tissue culture cells. (A) Growth of ovarian tissue culture cells treated with
STAMP siRNA relative to Lamin siRNA. The growth of cells 4 days after being transfected with STAMP siRNA or Lamin siRNA was determined as
in Fig. 1. The average data ± S.E.M. for 2-6 determinations (n = 12 for HeyA8 cells) are plotted as growth of cells treated with STAMP siRNA as
percent of growth of cells treated with Lamin siRNA. * P < 0.05, ** P < 0.005, *** P < 0.0005. (B) Growth rate vs. STAMP mRNA levels. The relative
growth rate (STAMP siRNA vs. Lamin siRNA) of each of the cell lines in A (± S.E.M.) was plotted against the level of STAMP mRNA in the same
cells after siRNA treatment relative to HeyA8 cells (± S.E.M.; length of bar may be less than symbol) given in Table 2. Straight line is the best fit
by Kaleidagraph (R
2 = 0.016).
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the dose-response curve to higher steroid concentrations
relative to that seen with vector control VA clone cells
(Figs. 4A&B). Similarly, the elevated STAMP in S13
cells decreases both the Amax and the partial agonist
activity of the antiglucocorticoid Dex-mesylate (%DM)
(Fig 4B). These changes are statistically significant for
each parameter in the presence of both 10 and 30 ng of
transfected GR.
A variety of factors could be responsible for the effects
of STAMP in Figs. 4A&B being opposite from expected
[14]. Two well-known factors that cause increases in
Amax, and partial agonist activity, and decreases in EC50
are GR itself and the coactivator TIF2 [14,27,28]. We
therefore asked whether higher levels of either GR or
TIF2 in VA cells might account for the results of Figs.
4A&B. Unfortunately, the amount of GR protein is too
low to detect by Western blotting, even after transient
transfection with 30 ng of GR plasmid (data not shown).
qRT-PCR was therefore used to determine the GR
mRNA levels, which were found to be very similar in
the two cell lines both with and without transfected GR
plasmid (Fig. 4C). Likewise, Western blotting revealed
equal TIF2 protein levels in clone VA and S13 cells
both with and without transfected GR (Fig. 4D). Thus,
the differences between VA and S13 cells in Figs. 4A&B
cannot be explained by VA cells possessing greater
amounts of GR and/or TIF2 than S13 cells. We con-
clude that unidentified cell-specific properties can
further alter the effects of changing levels of STAMP on
t h ee x p r e s s i o no ft h es a m eg e n e ( s )i nd i f f e r e n tc e l l s .
Therefore, just as was observed for the growth of ovar-
ian cancer cells upon depletion of endogenous STAMP,
the other known effects of STAMP are also cell-line
dependent.
Discussion
We report that STAMP affects the physiologically rele-
vant activity of cell growth apparently independent of
several steroid hormones. STAMP was initially charac-
terized as a new factor that bound to, and augmented
the ability of, the coactivator TIF2 to modulate the tran-
scriptional properties GR, AR, and PR [15-17]. The ster-
oid-independent effects of STAMP on the growth of a
variety of cells represent a new activity that differs with
the cell line, even within the same cell type. Increased
levels of stably transfected STAMP inhibit the growth
rate of human embryonic kidney 293 cells while all pos-
sible growth responses with changing STAMP are seen
in an assortment of ovarian cancer cell lines. We also
find a significant correlation between the level of
STAMP mRNA and the presence of ovarian cancer.
Stage I-III tumor samples possess significantly higher
levels of STAMP mRNA.
STAMP was increased in expression in malignant
epithelial ovarian cancer compared to normal ovary of
unknown epithelial component and the epithelial tumor
of low malignant potential. In view of the known het-
erogeneity of ovarian cancers [24,25], the varied
responses to silencing of STAMP in the ovarian cancer
cell lines suggest that there may be a select subset of
ovarian cancers in which STAMP may regulate behavior.
Epithelial ovarian cancer, while initiating in a steroid
hormone sensitive organ and known to have functional
ER and PR, has not been shown to be steroid hormone
driven as in prostate and breast cancer. The lack of
response to steroid hormones found herein may be an
e a r l ys i g n a la st oan e wr o l ef o rS T A M Pt h a tm a yu l t i -
mately explain the altered growth with modulation of
STAMP in ovarian cancers. This hypothesis, beyond the
scope of the current work, warrants further
investigation.
Studies with eleven tissue culture cell lines of ovarian
cancer revealed a cell line-dependent effect of reduced
STAMP mRNA, with increased or decreased growth
rates seen in many lines and no changes in others. Iden-
tical cell-specific responses are seen in Fig. 4 regarding
another activity of STAMP: its ability to modulate var-
ious parameters of GR-regulated gene induction. Thus,
the effects of STAMP appear to be sensitive to unknown
cell-specific factors. These varying consequences of
STAMP are reminiscent of CBP and p300, which can
display gene repressive activity [27,29-31] in addition to
its more common coactivator properties [10,13]. For
STAMP, the different responses are unrelated to the
absolute gene expression level of STAMP after knock-
down with STAMP siRNA (Fig. 3B). There is also no
direct correlation between the growth rate of the cells
and the amounts of seven common growth factors and
kinases. GEO file searches uncovered several proteins,
the expression of which shows some correlation with
STAMP on various platforms, but no consistent connec-
tion of any protein was evident across the different plat-
forms (data not shown). Thus we have not yet identified
the molecular cause for STAMP’s effects on cell growth.
Nevertheless, given the heterogeneity of ovarian cancers,
the statistically significant effect of decreased STAMP
mRNA on the growth rates of 5 of 11 ovarian cancer
tissue culture cell lines is consistent with an effect that
merits further examination.
The steroid-independent effect of STAMP on the
growth of stably transfected 293 cells appears to reflect
a new activity in addition to its ability to alter the prop-
erties of gene induction by GR, PR, and AR [15,16]. The
only other characterized domain of STAMP is the tyro-
sine tubulin ligase-like domain in the amino-terminal
third of the molecule, which overlaps the region encod-
ing polyglutamylation activity in some TTL domain
He et al. BMC Cancer 2010, 10:128
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Page 8 of 11proteins including STAMP [18]. We have confirmed
that STAMP is able to polyglutamylate tubulin and a
few other unidentified proteins (He and Simons, data
not shown). While the TTL domain, and polyglutamyla-
tion activity, of STAMP are not required for its modula-
tion of GR induction properties [15], they could be
relevant for effects on cell growth. It is also possible
that steroids will be found to influence the growth prop-
erties of the ovarian cancer tissue culture cell lines as
their response to different levels of STAMP is often dif-
ferent from that of the 293 cells, where growth is unaf-
fected by steroids. Thus, understanding the possible role
of STAMP in ovarian cancer may lead to new insight to
the deadly disease.
Figure 4 Effect of elevated STAMP on the properties of GR induction of GREtkLUC reporter gene in 293 cells. (A) Dose-response curves
for GR induction of GREtkLUC reporter with varying amounts of transiently transfected GR plasmid. S13 (containing stably transfected STAMP)
and vector control (VA) cells were cotransfected with GREtkLUC reporter and the indicated amounts of GR-encoding plasmid. Dose-response
curves were conducted and plotted as described by Tao et al. [32]. (B) Modulation of Amax, partial agonist activity of the antiglucocorticoid Dex-
Mes (%DM), and EC50 by elevated STAMP. Four independent experiments with clone S13 and VA cells such as in A, which included assaying the
activity of 1 μM Dex-Mes, were analyzed to yield Amax and EC50 in addition to partial agonist activity of 1 μM Dex-Mes (%DM). The average
values ± S.E.M. are plotted. * P < 0.05, ** P < 0.005, *** P < 0.0005 for clone S13 vs. the similarly treated clone VA sample. (C) GR mRNA levels in
VA and S13 cells. qRT-PCR was used as described in Materials and Methods to determine the level of GR mRNA in VA and S13 cells with or
without 30 ng of transiently transfected GR plasmid (± S.E.M. of triplicates). (D) Western blot with TIF2 antibody of cell lysates from cells
transfected with no, or 30 ng of GR plasmid. The lower panel shows the equal levels of the loading control, a-tubulin, in each sample.
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This study indicates that one physiological function of
the newly described transcriptional cofactor STAMP in
several settings is to modify cell growth rates in a
manner that can be independent of steroid hormones
and may participate in the progression of human can-
cers. Screening of eight common human cancers
revealed that Stage I-III tumor samples of ovarian can-
cer appear to possess significantly higher levels of
STAMP mRNA. Studies with eleven tissue culture cell
lines of ovarian cancer uncovered a cell line-dependent
effect of reduced STAMP mRNA on cell growth rates.
In view of the heterogeneity of ovarian tumors coupled
with the dearth of diagnostic tests for ovarian cancers,
the current observations suggest that STAMP levels
may be of diagnostic value in ovarian cancers and
could influence the progression of a sub-set of ovarian
tumors.
Additional file 1: STAMP mRNA levels in panel of 8 common human
cancers. The characterization of each sample in a commercially available
panel of 8 common human cancers (Origene) is listed. Also given are the
Ct values from the qRT-PCR assays and the calculation of the abundance
of STAMP mRNA in each sample, relative to the first sample (A1), which
was arbitrarily chosen.
Additional file 2: STAMP mRNA levels in panels human ovarian
cancers. The characterization of each sample in two different
commercially available panels of human ovarian cancer (Origene; total
samples = 96) is presented. Also given are the Ct values from the qRT-
PCR assays, the average Ct value (and S.D.) of all samples in each Stage,
and the p value of the average STAMP Ct value of each Stage vs. the
Stage 0 value.
Acknowledgements
Acknowledgements: We thank Lei Bao (Virginia Tech, Blacksburg, Virginia) for
assistance with the GEO and Bruce M. Raaka and Elizabeth Geras-Raaka
(NIDDK/NIH) for help with the FACS and cell counting. This research was
supported by the Intramural Research Program of the NIH, NIDDK and the
Center for Cancer Research, NCI, NIH.
Author details
1Steroid Hormones Section, Clinical Endocrinology Branch, NIDDK, National
Institutes of Health, Bethesda, MD 20892-1772, USA.
2Lab of Structural
Sciences, Van Andel Institute, 333 Bostwick Avenue, Grand Rapids, MI 49503,
USA.
3Molecular Signaling Section, Medical Oncology Branch, NCI, National
Institutes of Health, Bethesda, MD 20892, USA.
Authors’ contributions
YH participated in conceiving the study, designing the experiments,
performing the studies with human cancer panels and cells, and revising the
manuscript. JAB conducted the experiments in HEK293 cells and helped
with manuscript revisions. ECK contributed in the design of the experiments
and the revision of the manuscript, SSS participated in conceiving the study,
designing the experiments, revising the manuscript, and wrote the initial
draft of the paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 27 August 2009 Accepted: 7 April 2010
Published: 7 April 2010
References
1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P,
Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES,
Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR,
Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-
Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N,
Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: Core signaling
pathways in human pancreatic cancers revealed by global genomic
analyses. Science 2008, 321:1801-1806.
2. Wang RS, Yeh S, Tzeng CR, Chang C: Androgen Receptor Roles in
Spermatogenesis and Fertility: Lessons from Testicular Cell-Specific
Androgen Receptor Knockout Mice. Endocr Rev 2009.
3. Hewitt SC, Harrell JC, Korach KS: Lessons in estrogen biology from
knockout and transgenic animals. Annu Rev Physiol 2005, 67:285-308.
4. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O’Malley BW,
Lydon JP: Progesterone involvement in breast development and
tumorigenesis–as revealed by progesterone receptor “knockout” and
“knockin” mouse models. Steroids 2003, 68:779-787.
5. Gradishar WJ, Jordan VC: Clinical potential of new antiestrogens. J Clin
Oncol 1997, 15:840-852.
6. Akaza H: Current status and prospects of androgen depletion therapy for
prostate cancer. Best Pract Res Clin Endocrinol Metab 2008, 22:293-302.
7. Cole TJ: Glucocorticoid action and the development of selective
glucocorticoid receptor ligands. Biotechnol Annu Rev 2006, 12:269-300.
8. Funder JW: RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005,
93:121-125.
9. Schiffrin EL: Effects of aldosterone on the vasculature. Hypertension 2006,
47:312-318.
10. McKenna NJ, O’Malley BW: Combinatorial control of gene expression by
nuclear receptors and coregulators. Cell 2002, 108:465-474.
11. Nagy L, Schwabe JW: Mechanism of the nuclear receptor molecular
switch. Trends Biochem Sci 2004, 29:317-324.
12. Simons SS Jr: How much is enough? Modulation of dose-response curve
for steroid receptor-regulated gene expression by changing
concentrations of transcription factor. Current Topics in Medicinal
Chemistry 2006, 6:271-285.
13. Rosenfeld MG, Lunyak VV, Glass CK: Sensors and signals: a coactivator/
corepressor/epigenetic code for integrating signal-dependent programs
of transcriptional response. Genes Dev 2006, 20:1405-1428.
14. Simons SS Jr: What goes on behind closed doors: physiological versus
pharmacological steroid hormone actions. Bioessays 2008, 30:744-756.
15. He Y, Simons SS Jr: STAMP: a novel predicted factor assisting TIF2 actions
in glucocorticoid receptor-mediated induction and repression. Mol Cell
Biol 2007, 27:1467-1485.
16. Szapary D, Song L-N, He Y, Simons SS Jr: Differential modulation of
glucocorticoid and progesterone receptor transactivation. Mol Cell
Endocrinol 2008, 283:114-126.
17. Sun Y, Tao Y, Kagan BL, He Y, Simons SS Jr: Modulation of transcription
parameters in glucocorticoid receptor-mediated repression. Mol Cell
Endocrinol 2008, 295:59-69.
18. Janke C, Rogowski K, Wloga D, Regnard C, Kajava AV, Strub JM, Temurak N,
van Dijk J, Boucher D, van Dorsselaer A, Suryavanshi S, Gaertig J, Edde B:
Tubulin polyglutamylase enzymes are members of the TTL domain
protein family. Science 2005, 308:1758-1762.
19. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA
Cancer J Clin 2001, 51:15-36.
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007.
CA Cancer J Clin 2007, 57:43-66.
21. Leung EH, Leung PC, Auersperg N: Differentiation and growth potential
of human ovarian surface epithelial cells expressing temperature-
sensitive SV40 T antigen. In Vitro Cell Dev Biol Anim 2001, 37:515-521.
22. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J
Clin 2002, 52:23-47.
23. Cvetkovic D: Early events in ovarian oncogenesis. Reprod Biol Endocrinol
2003, 1:68.
24. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S,
Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J,
Swenerton K, Gilks CB, Huntsman D: Ovarian carcinoma subtypes are
different diseases: implications for biomarker studies. PLoS Med 2008, 5:
e232.
He et al. BMC Cancer 2010, 10:128
http://www.biomedcentral.com/1471-2407/10/128
Page 10 of 1125. Malek A, Schafer R, Tchernitsa O: Target genes suitable for silencing
approaches and protein product interference in ovarian epithelial
cancer. Cancer Treat Rev .
26. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D,
Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N,
Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK,
Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V,
Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J,
Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G,
Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L,
Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H,
Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P,
Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA,
Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH,
Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL,
Olson JE, Meijers-Heijboer H, Ouweland van den A, Uitterlinden A,
Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL,
McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H,
Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A,
Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA: Genome-
wide association study identifies novel breast cancer susceptibility loci.
Nature 2007, 447:1087-1093.
27. Szapary D, Huang Y, Simons SS Jr: Opposing effects of corepressor and
coactivators in determining the dose-response curve of agonists, and
residual agonist activity of antagonists, for glucocorticoid receptor
regulated gene expression. Mol Endocrinol 1999, 13:2108-2121.
28. Chen S, Sarlis NJ, Simons SS Jr: Evidence for a common step in three
different processes for modulating the kinetic properties of
glucocorticoid receptor-induced gene transcription. J Biol Chem 2000,
275:30106-30117.
29. Fonte C, Grenier J, Trousson A, Chauchereau A, Lahuna O, Baulieu EE,
Schumacher M, Massaad C: Involvement of {beta}-catenin and unusual
behavior of CBP and p300 in glucocorticosteroid signaling in Schwann
cells. Proc Natl Acad Sci USA 2005, 102:14260-14265.
30. Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S, Hormaeche I,
McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A: Histone
acetyltransferase activity of p300 is required for transcriptional
repression by the promyelocytic leukemia zinc finger protein. Mol Cell
Biol 2005, 25:5552-5566.
31. Santoso B, Kadonaga JT: Reconstitution of chromatin transcription with
purified components reveals a chromatin-specific repressive activity of
p300. Nat Struct Mol Biol 2006, 13:131-139.
32. Tao Y-G, Xu Y, Xu HE, Simons SSJ: Mutations of glucocorticoid receptor
differentially affect AF2 domain activity in a steroid-selective manner to
alter the potency and efficacy of gene induction and repression.
Biochemistry 2008, 47:7648-7662.
Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.
biomedcentral.com/1471-2407/10/128/prepub
doi:10.1186/1471-2407-10-128
Cite this article as: He et al.: STAMP alters the growth of transformed
and ovarian cancer cells. BMC Cancer 2010 10:128.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
He et al. BMC Cancer 2010, 10:128
http://www.biomedcentral.com/1471-2407/10/128
Page 11 of 11